


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(withdrawn):** A method of inhibiting~~An inhibitor of IL-6 production comprising administering to a subject in need of treatment an effective amount of,~~ a hydroxamic acid derivative of the formula (I):



wherein, R¹ is

- (a) C1-8 alkyl,
- (b) C2-8 alkenyl,
- (c) C2-8 alkynyl,
- (d) halogen,
- (e) nitro,
- (f) nitrile,
- (g) trifluoromethyl,
- (h) trifluoromethoxy,
- (i) —OR²,
- (j) —SR²,

- (k) NR^3R^4 ;
- (l) COR^5 ;
- (m) ~~keto~~;
- (n) Cyc1;
- (o) C1-8 alkyl substituted by $-\text{OR}^2$, $-\text{SR}^2$, $-\text{NR}^3\text{R}^4$, $-\text{COR}^5$ or Cyc1,
- (p) $-\text{SO}_2\text{R}^{10}$;
- (q) $\text{O}-(\text{C1-8 alkylene})-\text{OR}^{11}$;
- (r) C1-8 alkyl substituted by nitrile, $-\text{SO}_2\text{R}^{10}$ or $\text{O}-(\text{C1-8 alkylene})-\text{OR}^{11}$;
- (s) $\text{O}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$;
- (t) $\text{S}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$;
- (u) C1-8 alkyl substituted by $-\text{O}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$ or $-\text{S}-(\text{C1-8 alkylene})-$
 $\text{NR}^{12}\text{R}^{13}$,
- (v) C2-8 alkenyl substituted by $-\text{OR}^2$, $-\text{SR}^2$, $-\text{NR}^3\text{R}^4$, $-\text{COR}^5$, Cyc1, nitrile, $-\text{SO}_2\text{R}^{10}$,
 $-\text{O}-(\text{C1-8 alkylene})-\text{OR}^{11}$, $-\text{O}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$ or $-\text{S}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$ or
- (w) C2-8 alkynyl substituted by $-\text{OR}^2$, $-\text{SR}^2$, $-\text{NR}^3\text{R}^4$, $-\text{COR}^5$, Cyc1, nitrile, $-\text{SO}_2\text{R}^{10}$,
 $-\text{O}-(\text{C1-8 alkylene})-\text{OR}^{11}$, $-\text{O}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$ or $-\text{S}-(\text{C1-8 alkylene})-\text{NR}^{12}\text{R}^{13}$,

R^2 is hydrogen, C1-8alkyl, C2-9 acyl or Cyc1,

R^3 and R^4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R^5 is hydroxy, C1-8 alkyl, C1-8 alkoxy, $-\text{NR}^6\text{R}^7$ or Cyc1,

R^6 and R^7 are each independently hydrogen, C1-8 alkyl or Cyc1,

R^{10} is C1-8 alkyl or Cyc1,

Cyc1 is morpholine, piperidine or piperazine~~C3-7 mono carbocyclic ring or 5-7 membered mono cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom~~;

R¹¹ is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;

R¹² and R¹³ are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

m is 0 or an integer of 1-5;

ring A is a benzene ring~~C3-15 mono, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s)~~;

ring B is a benzene ring~~C5-15 mono, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s)~~;

E is a bond, -CH=CH- or -C≡C-;

R⁸ is

- (a) C1-8 alkyl,
- (b) C1-8 alkoxy,
- (c) halogen,
- (d) nitro,
- (e) nitrile,
- (f) trifluoromethyl or
- (g) trifluoromethoxy,


with the proviso that when E is a bond, then, optionally, R¹ and R⁸, taken together, may be optionally C1-4 alkylene;

n is 0 or an integer of 1-5;

R⁹ is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl;


a nontoxic salt thereof or a prodrug thereof, as an active ingredient.

2. (withdrawn): The methodinhibitor of IL-6 production described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by a compound of the formula (IA):




{wherein, R¹⁴ is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meanings as defined in claim 1.}.

3. (withdrawn): The methodinhibitor of IL-6 production described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by comprising a compound of the formula (IB):



{wherein, the all symbols have the same meanings as defined in claim 1.}.

4. (currently amended): A hydroxamic acid derivative of the formula (I):



wherein, R^1 is

- (a) C1-8 alkyl,
- (b) C2-8 alkenyl,
- (c) C2-8 alkynyl,
- (d) halogen;
- (e) nitro;
- (f) nitrile;
- (g) trifluoromethyl;
- (h) trifluoromethoxy;
- (i) $-OR^2$;
- (j) $-SR^2$;
- (k) $-NR^3R^4$;
- (l) $-COR^5$;
- (m) keto;
- (n) Cyc1,
- (o) C1-8 alkyl substituted by $-OR^2$, $-SR^2$, $-NR^3R^4$, $-COR^5$ or Cyc1,
- (p) $-SO_2R^{10}$;

Amendment Under 37 C.F.R. § 1.111
U.S. Serial No. 10/088,832

(q) ~~O (C1-8 alkylene) OR¹¹~~;

(r) ~~C1-8 alkyl substituted by nitrile, SO₂R¹⁰ or O (C1-8 alkylene) OR¹¹~~;

(s) ~~O (C1-8 alkylene) NR¹²R¹³~~;

(t) ~~S (C1-8 alkylene) NR¹²R¹³~~;

(u) C1-8 alkyl substituted by -O-(C1-8 alkylene)-NR¹²R¹³- or -S-(C1-8 alkylene)-NR¹²R¹³,

(v) C2-8 alkenyl substituted by -OR², -SR², -NR³R⁴, -COR⁵, Cyc1, nitrile, -SO₂R¹⁰, -O-(C1-8 alkylene)-OR¹¹, -O-(C1-8 alkylene)-NR¹²R¹³ or -S-(C1-8 alkylene)-NR¹²R¹³ or

(w) C2-8 alkynyl substituted by -OR², -SR², -NR³R⁴, -COR⁵, Cyc1, nitrile, -SO₂R¹⁰, -O-(C1-8 alkylene)-OR¹¹, -O-(C1-8 alkylene)-NR¹²R¹³ or -S-(C1-8 alkylene)-NR¹²R¹³,

R² is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R³ and R⁴ are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R⁵ is hydroxyl, C1-8 alkyl, C1-8 alkoxy, -NR⁶R⁷ or Cyc1,

R⁶ and R⁷ are each independently hydrogen, C1-8 alkyl or Cyc1,

R¹⁰ is C1-8 alkyl or Cyc1;

Cyc1 is morpholine, piperidine or piperazine C3-7 mono carbocyclic ring or 5-7

membered mono cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom;:

R¹¹ is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;

R¹² and R¹³ are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;

m is 0 or an integer of 1-5;

ring A is a benzene ring~~C3-15 mono-, bi- or tri-carboyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);~~

ring B is a benzene ring~~C5-15 mono-, bi- or tri-carboyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);~~

E is a bond, -CH=CH- or -C≡C-;

R⁸ is

- (a) C1-8 alkyl,
- (b) C1-8 alkoxy,
- (c) halogen,
- (d) nitro,
- (e) nitrile,
- (f) trifluoromethyl or
- (g) trifluoromethoxy,

with the proviso that when E is a bond then, optionally, R¹ and R⁸, taken together, is C1-4 alkylene optionally;


n is 0 or an integer of 1-5;

R⁹ is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl;

~~with the proviso that when E is CH=CH or C≡C, ring A is C3-7 mono-carbocyclic ring or 5-7 membered mono cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom,~~


a nontoxic salt thereof or a prodrug thereof.

5. (currently amended): The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IA):



{wherein, R¹⁴ is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meaning as defined in claim [[1.]]] 4.

6. (currently amended): The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IB):



{wherein, the all symbols have the same meaning as defined in claim [[1.]]] 4.

7. (currently amended): The compound described in claim 4, wherein E is a bond and ~~ring A is C3-15 mono, bi or tri carbocyclic ring.~~

8. (canceled)

9. (currently amended): The compound described in claim 4, wherein E is -CH=CH- or -C≡C- and ring A is C₃-7 mono carbocyclic ring.

10. (canceled)

11. (currently amended): The compound described in claim 4, which is

- (1) N hydroxy 6 (4 (4 chlorophenyl)phenyl) 6 hydroxyhexanamide,
- (2) N hydroxy 6 (4 biphenyl) 6 hydroxyhexanamide,
- (3) N hydroxy 6 (4 cyclohexylphenyl) 6 hydroxyhexanamide,
- (4) N hydroxy 6 (4 (4 methylphenyl)phenyl) 6 hydroxyhexanamide,
- (5) N hydroxy 6 (4 (4 methoxyphenyl)phenyl) 6 hydroxyhexanamide,
- (6) N hydroxy 6 (4 (trans 4 propylecyclohexyl)phenyl) 6 hydroxyhexanamide,
- (7) (R) N hydroxy 6 (4 (4 chlorophenyl)phenyl) 6 hydroxyhexanamide,
- (8) (S) N hydroxy 6 (4 (4 chlorophenyl)phenyl) 6 hydroxyhexanamide,
- (9) N hydroxy 6 (4 (benzofuran-2-yl)phenyl) 6 hydroxyhexanamide,
- (10) N hydroxy 6 (4 (pyridin-4-yl)phenyl) 6 hydroxyhexanamide,
- (11) N hydroxy 6 (4 (pyridin-3-yl)phenyl) 6 hydroxyhexanamide,
- (12) N hydroxy 6 (4 (2 chlorophenyl)phenyl) 6 hydroxyhexanamide,
- (13) N hydroxy 6 (4 (3 chlorophenyl)phenyl) 6 hydroxyhexanamide,
- (14) N hydroxy 6 (4 (4 bromophenyl)phenyl) 6 hydroxyhexanamide,
- (15) N hydroxy 6 (4 (thiophen-2-yl)phenyl) 6 hydroxyhexanamide,
- (16) N hydroxy 6 (4 (furan-2-yl)phenyl) 6 hydroxyhexanamide,
- (17) N hydroxy 6 (4 (1,3 dioxy 2,3 dihydroinden-5-yl)phenyl) 6 hydroxyhexanamide,

- (18) N hydroxy 6 (4 (4 methylthiophenyl)phenyl) 6 hydroxyhexanamide,
(19) N hydroxy 6 (4 (naphthalen-1-yl)phenyl) 6 hydroxyhexanamide,
(20) N hydroxy 6 (4 (naphthalen-2-yl)phenyl) 6 hydroxyhexanamide,
(21) N hydroxy 6 (4 (4 acetylphenyl)phenyl) 6 hydroxyhexanamide,
(22) N hydroxy 6 (4 (4 hydroxyphenyl)phenyl) 6 hydroxyhexanamide,
(23) N hydroxy 6 (4 (dibenzofuran-4-yl)phenyl) 6 hydroxyhexanamide,
(24) N hydroxy 6 (4 (2 methoxyphenyl)phenyl) 6 hydroxyhexanamide,
(25) N hydroxy 6 (4 (3 methoxyphenyl)phenyl) 6 hydroxyhexanamide,
(26) N hydroxy 6 (4 (4 trifluoromethylphenyl)phenyl) 6 hydroxyhexanamide,
(27) N hydroxy 6 (4 (4 t-butylphenyl)phenyl) 6 hydroxyhexanamide,
(28) (R) N hydroxy 6 [4 (5 methylbenzoxazol-2-yl)phenyl] 6 hydroxyhexanamide,
(29) (R) N hydroxy 6 [4 (benzoxazol-2-yl)phenyl] 6 hydroxyhexanamide,
(30) (R) N hydroxy 6 [4 (2 (4 methylthiophenyl)ethynyl)phenyl] 6 hydroxyhexanamide,
(31) (R) N hydroxy 6 [4 (4 methylthiophenyl)phenyl] 6 hydroxyhexanamide,
(32) (R) N hydroxy 6 [4 (4 (dimethylaminomethyl)phenyl)phenyl] 6 hydroxyhexanamide,
(33) N hydroxy 6 (4 (trans-4 butylecyclohexyl)phenyl) 6 hydroxyhexanamide,
(34) N hydroxy 6 (4 (trans-4 hydroxycyclohexyl)phenyl) 6 hydroxyhexanamide,
(35) N hydroxy 6 (4 cyclopentylphenyl) 6 hydroxyhexanamide,
(36) N hydroxy 6 [4 (morpholin-4-yl)phenyl] 6 hydroxyhexanamide,
(37) N hydroxy 6 [3 (4 chlorophenyl)phenyl] 6 hydroxyhexanamide,

- (38) ~~N hydroxy 6 [2 (4 chlorophenyl)phenyl] 6 hydroxyhexanamide,~~
- (39) ~~N hydroxy 6 [4 ((1E)-2 phenylvinyl)phenyl] 6 hydroxyhexanamide,~~
- (40) ~~N hydroxy 6 [4 ((1E)-2 (pyridin-4-yl)vinyl)phenyl] 6 hydroxyhexanamide,~~
- (41) ~~N hydroxy 6 [4 ((1E)-2 (pyridin-2-yl)vinyl)phenyl] 6 hydroxyhexanamide,~~
- (42) ~~N hydroxy 6 [4 (4 chlorophenyl)phenyl] 6 hydroxyheptanamide,~~
- (43) ~~N hydroxy 6 [4 (4 chlorophenyl)phenyl] 6 hydroxy-7 octenamide,~~
- (44) ~~N hydroxy 6 (4 biphenyl) 6 hydroxyheptanamide,~~
- (45) ~~(+) N hydroxy 6 [4 (4 ethylphenyl)phenyl] 6 hydroxyheptanamide,~~
- (46) ~~(-) N hydroxy 6 [4 (4 ethylphenyl)phenyl] 6 hydroxyheptanamide,~~
- (47) ~~(R) N hydroxy 6 (4 biphenyl) 6 hydroxyhexanamide,~~
- (48) ~~(R) N hydroxy 6 [4 (4 methylphenyl)phenyl] 6 hydroxyhexanamide,~~
- (49) ~~(R) N hydroxy 6 [4 (3 methylphenyl)phenyl] 6 hydroxyhexanamide,~~
- (50) ~~(R) N hydroxy 6 [4 (benzoxazol-2-yl)phenyl] 6 hydroxyhexanamide,~~
- (51) ~~(R) N hydroxy 6 [4 (2 phenylethyynyl)phenyl] 6 hydroxyhexanamide,~~
- (52) ~~(R) N hydroxy 6 [4 (benzothiophen-2-yl)phenyl] 6 hydroxyhexanamide,~~
- (53) ~~(R) N hydroxy 6 [4 (4 cyanomethyl)phenyl] 6 hydroxyhexanamide,~~
- (54) ~~(R) N hydroxy 6 [4 (4 ethylphenyl)phenyl] 6 hydroxyhexanamide,~~
- (55) ~~(R) N hydroxy 6 [4 (4 propylphenyl)phenyl] 6 hydroxyhexanamide,~~
- (56) ~~(R) N hydroxy 6 [4 (4 biphenyl)phenyl] 6 hydroxyhexanamide,~~
- (57) ~~(R) N hydroxy 6 [4 (1 methylpiperidin-4-yl)phenyl] 6 hydroxyhexanamide,~~
- (58) ~~(R) N hydroxy 6 [4 (indol-2-yl)phenyl] 6 hydroxyhexanamide,~~

- (59) (R) N hydroxy 6 [4 (4 cyanophenyl)phenyl] 6 hydroxyhexanamide,
(60) (R) N hydroxy 6 [4 phenyl 2 methylphenyl] 6 hydroxyhexanamide,
(61) (R) N hydroxy 6 (4 cycloheptylphenyl) 6 hydroxyhexanamide,
(62) (R) N hydroxy 6 (9,10 dihydrophenanthren 2 yl) 6 hydroxyhexanamide,
(63) (R) N hydroxy 6 [4 (1 ethoxycarbonylpiperidin 4 yl)phenyl] 6 hydroxyhexanamide,
(64) (R) N hydroxy 6 [4 (4 (N methylcarbamoyl)phenyl)phenyl] 6 hydroxyhexanamide,
(65) (R) N hydroxy 6 (4 cyclohexylphenyl) 6 hydroxyhexanamide,
(66) (R) N hydroxy 6 [4 (5 hydroxybenzofuran 2 yl)phenyl] 6 hydroxyhexanamide,
(67) (R) N hydroxy 6 [4 (2 (4 methylphenyl)ethynyl)phenyl] 6 hydroxyhexanamide,
(68) (R) N hydroxy 6 [4 ((1E) 2 (4 methylphenyl)vinyl)phenyl] 6 hydroxyhexanamide,
(69) (R) N hydroxy 6 [4 (4 trifluoromethoxyphenyl)phenyl] 6 hydroxyhexanamide,
(70) (R) N hydroxy 6 [4 (4 ethylthiophenyl)phenyl] 6 hydroxyhexanamide,
(71) (R) N hydroxy 6 [4 (4 methoxyphenyl)phenyl] 6 hydroxyhexanamide,
(72) (R) N hydroxy 6 [4 (4 (1 methylethyl)phenyl)phenyl] 6 hydroxyhexanamide,
(73) (R) N hydroxy 6 [4 (4 (N,N dimethylcarbamoylmethyl)phenyl)phenyl] 6 hydroxyhexanamide,
(74) (R) N hydroxy 6 [4 (benzothiazol 2 yl)phenyl] 6 hydroxyhexanamide,
(75) (R) N hydroxy 6 [4 (4 (methoxymethoxymethyl)phenyl)phenyl] 6 hydroxyhexanamide,
(76) (R) N hydroxy 6 [4 (6 methoxybenzoxazol 2 yl)phenyl] 6 hydroxyhexanamide,

(77) (R)-N-hydroxy-6-[4-(6-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide;

(78) (R)-N-hydroxy-6-[4-(4-methoxymethylphenyl)phenyl]-6-hydroxyhexanamide;

(79) (R)-N-hydroxy-6-[4-(5-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide;

(80) (R)-N-hydroxy-6-[4-(4-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide;

(81)(1) (R)-N-hydroxy-6-[4-(4-(piperidin-1-ylmethyl)phenyl)phenyl]-6-

hydroxyhexanamide,

(82) (R)-N-hydroxy-6-[4-(4-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide;

(83) (R)-N-hydroxy-6-[4-(6-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide;

(84) (R)-N-hydroxy-6-[4-((1E)-2-(4-methylthiophenyl)vinyl)phenyl]-6-

hydroxyhexanamide;

(85) (R)-N-hydroxy-6-[4-(5-methoxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide;

(86) (R)-N-hydroxy-6-[4-(5-methylthiobenzofuran-2-yl)phenyl]-6-hydroxyhexanamide;

(87) (R)-N-hydroxy-6-[4-(4-(2-(dimethylamino)ethyl)phenyl)phenyl]-6-

hydroxyhexanamide;

(88) (R)-N-hydroxy-6-[4-(4-(2-(dimethylamino)ethoxy)phenyl)phenyl]-6-

hydroxyhexanamide;

(89) (R)-N-hydroxy-6-[4-(4-(2-diethylamino)ethyl)phenyl]phenyl]-6-

hydroxyhexanamide;

(90) (R)-N-hydroxy-6-[4-(4-(2-hydroxyethyl)phenyl)phenyl]-6-hydroxyhexanamide;

(91) (S)-N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide;

(92) (S)-N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide;

(93) (S) ~~N hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

(94) (S) ~~N hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

(95) (S) ~~N hydroxy-6-[4-(4-dimethylaminomethyl)phenyl]phenyl]-6-hydroxyhexanamide,~~

(96)(2) (R)-N-hydroxy-6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,

(97) (R) ~~N hydroxy-6-[4-(4-dipropylaminomethyl)phenyl]phenyl]-6-hydroxyhexanamide,~~

(98) (R) ~~N hydroxy-6-(5-phenylthiophen-2-yl)-6-hydroxyhexanamide,~~

(99) (R) ~~N hydroxy-6-(5-phenylbenzofuran-2-yl)-6-hydroxyhexanamide,~~

(100) (R) ~~N hydroxy-6-[4-(4-methoxycarbonyl)phenyl]phenyl]-6-hydroxyhexanamide,~~

(101) (R) ~~N hydroxy-6-[4-(4-carboxyphenyl)phenyl]-6-hydroxyhexanamide,~~

(102) (R) ~~N hydroxy-6-[4-(4-methylsulfonylphenyl)phenyl]-6-hydroxyhexanamide,~~

(103) (R) ~~N hydroxy-6-[4-(4-hydroxymethylphenyl)phenyl]-6-hydroxyhexanamide,~~

(104)(3) (R)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,

(105)(4) (R)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-hydroxyhexanamide

or a nontoxic salt thereof.

12. (currently amended) The compound described in claim 5, which is:

- (1) ~~N (1-methoxy-1-methyl)ethoxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~
- (2) ~~N (1-methoxy-1-methyl)ethoxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide,~~
- (3) ~~(R) N (1-methoxy-1-methyl)ethoxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~
- (4) ~~(R) N (1-methoxy-1-methyl)ethoxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~
- (5) ~~(R) N (1-methoxy-1-methyl)ethoxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,~~
- (6) ~~(R) N (1-methoxy-1-methyl)ethoxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,~~
- (7) ~~(R) N (1-methoxy-1-methyl)ethoxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~
- (8)(1) ~~(R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~
- (9) ~~(R) N (1-methoxy-1-methyl)ethoxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~
- (10) ~~N-methoxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,~~

(11)(2) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,

(12)(3) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,

or a nontoxic salt thereof.

13. (Cancelled)